A detailed history of Core Alternative Capital transactions in Moderna, Inc. stock. As of the latest transaction made, Core Alternative Capital holds 5 shares of MRNA stock, worth $259. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5
Previous 5 -0.0%
Holding current value
$259
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$85.37 - $115.44 $10,244 - $13,852
-120 Reduced 96.0%
5 $0
Q4 2023

Feb 14, 2024

SELL
$69.51 - $104.43 $973 - $1,462
-14 Reduced 10.07%
125 $12,000
Q2 2023

Jul 27, 2023

BUY
$118.5 - $160.53 $829 - $1,123
7 Added 5.3%
139 $16,000
Q1 2023

Apr 18, 2023

BUY
$135.66 - $197.02 $1,899 - $2,758
14 Added 11.86%
132 $20,000
Q4 2022

Jan 31, 2023

SELL
$118.38 - $210.04 $118 - $210
-1 Reduced 0.84%
118 $21,000
Q3 2022

Oct 18, 2022

BUY
$118.07 - $194.18 $1,416 - $2,330
12 Added 11.21%
119 $14,000
Q2 2022

Aug 01, 2022

BUY
$117.13 - $176.59 $1,405 - $2,119
12 Added 12.63%
107 $15,000
Q1 2022

May 10, 2022

BUY
$126.46 - $235.05 $10,243 - $19,039
81 Added 578.57%
95 $16,000
Q4 2021

Feb 11, 2022

BUY
$225.82 - $368.51 $3,161 - $5,159
14 New
14 $4,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $20.3B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Core Alternative Capital Portfolio

Follow Core Alternative Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Alternative Capital, based on Form 13F filings with the SEC.

News

Stay updated on Core Alternative Capital with notifications on news.